ACLU -- Myriad Genetics lawsuit will become landmark case

May 14, 2009

The American Civil Liberties Union action in filing a lawsuit yesterday against Myriad Genetics is going to lead to one of the most important legal battles in the history of biotechnology, asserts Genetic Engineering & Biotechnology News (GEN). The ACLU charged that the patenting of two human genes linked to breast and ovarian cancer will inhibit medical research. The organization also claims that the patents are invalid and unconstitutional.

"This is going to turn into one of the watershed events in the evolution of the bioindustry," says John Sterling, Editor in Chief of GEN. "The pros and cons of patenting have been an ongoing, and often acrimonious series of debates, since the in re Chakrabarty decision in 1980. But this particular case seems to have taken on a life of its own with over fifteen plaintiffs. For while the specifically centers on the patentability of two cancer-related genes, the ACLU says it plans to challenge the entire concept of patenting genes. What we have here is one group, the ACLU and its allies, contending that gene patents stifle life science research and potentially harm the health of thousands of patients. On the other side are biotech companies who maintain that without gene patents research incentives are seriously diminished and innovation is smothered."

Kenneth I. Berns, M.D., Ph.D., Editor in Chief of the peer reviewed journal, Genetic Testing and Molecular Biomarkers, which is the official journal of the Genetic Alliance, says the "patenting of human genes is a bad idea and that healthcare in the U.S. would be enhanced if the ACLU suit prevails." Dr. Berns is also Director of the University of Florida Genetics Institute in Gainesville.

William Warren, partner at the Sutherland law firm, thinks the ACLU, in this case, is barking up the wrong tree. "The ACLU unexpectedly based its invalidity challenge on claims to unpatentable subject matter," he says. "The ACLU might have instead considered challenging the Myriad patents for obviousness." Warren and Sutherland colleague, Lei Fang, Ph.D., M.D., have authored a legal article, which will be published in the June 1 issue of GEN entitled "Patentability of Genetic Sequences Limited." It is now available online. (http://www.genengnews.com/news/bnitem.aspx?name=54504126&source=genwire)

Source: Mary Ann Liebert, Inc.

Explore further: The first UK medical school launches Google Glass technology in curriculum

add to favorites email to friend print save as pdf

Related Stories

ACLU: US Attorney OK'd GPS to track cell phones

Apr 23, 2009

(AP) -- The American Civil Liberties Union says the U.S. Attorney's Office for New Jersey under Christopher Christie, now a GOP gubernatorial candidate, tracked the whereabouts of citizens through their cell phones without ...

Madoff scandal's impact on the life sciences

Mar 17, 2009

While the Bernard Madoff Ponzi scheme led to the collapse of the Picower Foundation, a major benefactor for life science research, many bioindustry observers view the fallout from the scandal as a minor consequence in the ...

GEN highlights emerging biotechnology clusters

May 05, 2009

Although Boston, San Francisco, San Diego, and Cambridge (U.K.) are always near the top of most biotechnology cluster lists, other areas around the world are starting to pop up on the life science radar screen, reports Genetic ...

Los Angeles eyes action against hospitals

Nov 08, 2006

The Los Angeles city attorney's office has begun plans to file legal action against 10 hospitals suspected of abandoning discharged patients on skid row.

Recommended for you

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.